Therefore, the functional profile for G protein modulation of CBRs expressed in both prostate cancer cell lines is clearly distinct from canonical CBRs, most notably shown by a lack of agonist activity produced by the full CB1/CB2 agonist WIN-55.212-2 and full CB2-selective agonist GW-405-833. The gene discussed is CNR2; the disease is prostate carcinoma.